IDEXX Laboratories reports company news centered on veterinary diagnostics, software and animal-health testing. Recurring updates cover CAG Diagnostics recurring revenue, reference laboratory services, in-clinic analyzers, premium instrument placements and financial guidance tied to veterinary practice demand in the U.S. and international regions.
Company announcements also describe product innovation across pet healthcare, including IDEXX Cancer Dx testing, IDEXX inVue Dx, digital imaging systems such as Vue DR50 Plus, Web PACS software and connected workflow tools for veterinary practices. Other recurring topics include investor conference participation, governance and leadership updates, and products that support milk and water safety and livestock health.
IDEXX Laboratories (IDXX) reported third-quarter 2026 revenue of $1,214 million, with growth across its companion animal, water and livestock businesses. Revenue increased 10% as reported and organically; diluted earnings per share rose 18% to $4.01. CAG Diagnostics recurring revenue grew 11% as reported and organically. Gross margin reached 62.9%, up 110 basis points, while operating margin increased 100 basis points to 33.1%.
The company raised its 2026 revenue outlook to $4,741 million–$4,767 million and EPS outlook to $14.96–$15.16, but lowered expected operating margin to 32.1%–32.3%, including acquisition-related impacts. IDEXX acquired AI clinical assistant CoVet, with $5 million included in its updated revenue outlook. Quarterly inVue Dx placements exceeded 1,900, bringing the installed base to nearly 11,000 instruments.
IDEXX Laboratories (Nasdaq: IDXX) will release its third-quarter 2026 financial results on November 2, 2026, before the market opens.
An analyst conference call will begin at 8:30 a.m. ET that day. The webcast, prepared remarks transcript and Q3 2026 Earnings Snapshot will be accessible through the investor website. A webcast archive will be available after 1:00 p.m. ET that day for one year.
Chicago Pacific Founders (CPF) exited its investment in CoVetAI following the veterinary technology company's acquisition by IDEXX Laboratories (NASDAQ: IDXX).
The transaction marks the first realization—an investment exit—from the CPF Pet Fund's inaugural vehicle, which is now closed. CPF was CoVet's sole institutional investor. Financial terms were not disclosed.
CoVet develops an AI-powered clinical scribe and workflow platform for veterinary medicine. The CPF Pet Fund has made six portfolio investments to date and focuses on animal health, veterinary technology and pet wellness.
IDEXX Laboratories (IDXX) has expanded its Faecal Dx antigen testing platform in the United Kingdom to include taeniid tapeworm detection, covering Taenia and Echinococcus species.
The platform is described as detecting up to twice as many intestinal parasite infections earlier than faecal flotation alone and has been used in more than 50 million tests worldwide since its 2012 launch. With this addition, Faecal Dx now detects seven clinically relevant intestinal parasite groups, and UK IDEXX Reference Laboratories customers receive taeniid tapeworm detection at no additional cost. Positive taeniid results automatically trigger a complimentary follow-up Echinococcus RealPCR test, supporting management of parasites that carry zoonotic risk.
IDEXX Laboratories (IDXX) on September 16, 2026 acquired CoVetAI, an AI-native ambient listening and clinical workflow software provider for veterinary practices.
CoVet’s software automatically captures and organizes information across the patient journey, reducing documentation burden and saving clinicians time for both corporate groups and independent clinics worldwide. The business will be integrated into the IDEXX software ecosystem, which will continue to support other ambient scribe solutions and third-party integrations, and CoVet will also keep integrating with non-IDEXX practice management systems.
The acquisition reinforces IDEXX’s focus on AI and software as enablers of diagnostic insights, workflow efficiency, and practice performance, and is expected to expand global reach through integration with IDEXX VetConnect PLUS and support for geographies not currently served by IDEXX practice management systems. Financial terms were not disclosed.
IDEXX Laboratories (Nasdaq: IDXX) announced that President and CEO Mike Erickson and EVP and CFO Andrew Emerson will join a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026, from 10:45 am to 11:20 am (ET). A live audio webcast and archived replay will be accessible via the investors section of the IDEXX website.
IDEXX Laboratories (Nasdaq: IDXX) launched the Catalyst™ proBNP Test, described as the first and only dual-species, in-clinic NT-proBNP assay for cats and dogs, expanding cardiac diagnostics on its Catalyst platform, which has a global installed base of nearly 80,000 analyzers.
The quantitative point-of-care test provides laboratory-level cardiac biomarker results during the patient visit, supporting screening, diagnosis, and monitoring of heart disease, including differentiation of cardiac vs noncardiac respiratory distress and preoperative evaluations. According to IDEXX, Catalyst proBNP taps into an estimated $4 billion global cardiac testing opportunity and integrates with VetConnect™ PLUS for contextual result interpretation. North American availability is planned for October 2026, with international rollout to follow.
IDEXX Laboratories (NASDAQ: IDXX) reported second quarter 2026 revenues of $1,217 million, up 10% reported and 9% organic, driven by Companion Animal Group growth of 9%, Water growth of 15% and LPD growth of 11% as reported. CAG Diagnostics recurring revenue rose 11% reported and 10% organic, while the IDEXX inVue Dx™ installed base surpassed 9,000 instruments with over 1,600 placements in the quarter.
Diluted EPS was $4.27, up 18% reported and 15% comparable, including $0.14 per share of tax benefits from share-based compensation and a $0.06 benefit from year-over-year currency changes. Gross margin reached 64.0% and operating margin 35.0%, both expanding 140 basis points as reported.
IDEXX narrowed its 2026 revenue guidance to $4.700–$4.745 billion and raised its outlook for reported revenue growth to 9.1%–10.3% and organic growth to 8.5%–9.7%. The 2026 EPS outlook increased to $14.69–$14.94, $0.14 higher at midpoint than prior guidance, while incorporating a $15 million revenue headwind from updated foreign exchange estimates.
IDEXX (Nasdaq: IDXX) released its 2025 Corporate Responsibility Report, outlining progress on innovation, people and environmental goals. The company highlighted new diagnostics, including launch or launch-readiness for the IDEXX Cancer Dx™ Panel with canine lymphoma detection and new FNA cytology capabilities on the IDEXX inVue Dx™ Cellular Analyzer, and the ImageVue™ DR50 Plus Digital Imaging System, which combines AI with what the company describes as the industry’s lowest radiation dose.
According to IDEXX, its social initiatives helped enable access to care for more than 45,000 animals in underserved communities in 2025, bringing total support since 2022 to over 749,000 animals. The company reported 121,400 hours of employee learning, including 46,700 hours in STEM and AI, and more than 24,000 volunteer hours, exceeding its 15,000‑hour annual goal. Environmentally, IDEXX signed its first European virtual power purchase agreement, bringing total VPPAs to three, which it expects will cover 100% of its North American and European electricity consumption when operational, and reported that hybrid and electric vehicles made up about 42% of its commercial fleet at year-end 2025.
IDEXX Laboratories (NASDAQ: IDXX) will release its 2026 second quarter financial results on Tuesday, August 4, 2026, before market open, followed by an analyst conference call at 8:30 a.m. ET.
The company will also host its 2026 Investor Day on Thursday, August 13, 2026, at its Westbrook, Maine headquarters.